Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 5/20 | 0.41 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | FDPS | P14324 | 1/20 | 0.37 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.35 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.35 |
| ▸ | ABAT | P80404 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29956523 | 1.00 | TSHR (0.43) | TSHRALDH1A1CYP2A6ALDH1A3EGFR | |
| SCHEMBL1795902 | 0.84 | TSHR (0.43) | TSHRALDH1A1CYP2A6ALDH1A3EGFR | |
| SCHEMBL21479597 | 0.82 | XDH (0.44) | TSHRALDH1A1KDM4EPTGS2 | |
| SCHEMBL6899726 | 0.81 | ALDH1A1 (0.47) | TSHRALDH1A1CYP2A6EGFRKDM4E | |
| SCHEMBL16958999 | 0.80 | TSHR (0.43) | TSHRALDH1A1EGFRKDM4EPTGS2 | |
| SCHEMBL16952815 | 0.80 | TSHR (0.43) | TSHRALDH1A1KDM4EHPGDTDP1 | |
| SCHEMBL16249165 | 0.80 | ALDH1A1 (0.42) | TSHRALDH1A1CYP2A6ALDH1A3KDM4E | |
| SCHEMBL20590003 | 0.78 | ALDH1A1 (0.39) | TSHRALDH1A1CYP2A6ALDH1A3EGFR | |
| SCHEMBL13630983 | 0.77 | ALDH1A1 (0.40) | TSHRALDH1A1CYP2A6ALDH1A3EGFR | |
| SCHEMBL1395746 | 0.77 | ALDH1A1 (0.40) | TSHRALDH1A1CYP2A6ALDH1A3EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12258329-B2 | Pyrimidone derivatives as selective cytotoxic agents against HIV infected cells | MERCK SHARP & DOHME LLC (US) | 2025-03-25 | — | — | US | disclosed |
| CN-114026081-B | Pyridone derivatives as selective cytotoxic agents against HIV-infected cells | 默沙东有限责任公司 | 2025-02-11 | — | — | CN | disclosed |
| US-20240300965-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-09-12 | — | — | US | disclosed |
| EP-3972965-B1 | PYRIDINONE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS AGAINST HIV INFECTED CELLS | MERCK SHARP & DOHME LLC (US) | 2024-07-03 | — | — | EP | disclosed |
| US-11999746-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-06-04 | — | — | US | disclosed |
| EP-3898595-B1 | PYRIMIDONE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS AGAINST HIV INFECTED CELLS | MERCK SHARP & DOHME LLC (US) | 2024-05-01 | — | — | EP | disclosed |
| WO-2023208151-A1 | USP INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION | 北京华森英诺生物科技有限公司 | 2023-11-02 | — | — | WO | disclosed |
| CN-116621778-A | USP inhibitor, preparation method and application thereof | 北京华森英诺生物科技有限公司 | 2023-08-22 | — | — | CN | disclosed |
| US-20230250097-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | Apollo Therapeutics Limited (GB) | 2023-08-10 | — | — | US | disclosed |
| US-20220242847-A1 | PYRIDINONE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS AGAINST HIV INFECTED CELLS | MERCK SHARP & DOHME CORP. (US) | 2022-08-04 | — | — | US | disclosed |
| WO-2016011930-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-01-28 | — | — | WO | disclosed |
| US-20150284408-A1 | INHIBITORS OF DNA GYRASE FOR THE TREATMENT OF BACTERIAL INFECTIONS | KUMAR, AJAY, DR. (GB) | 2015-10-08 | — | — | US | disclosed |
| EP-2906216-A2 | INHIBITORS OF DNA GYRASE FOR THE TREATMENT OF BACTERIAL INFECTIONS | Vitas Pharma Research Private Limited (IN) | 2015-08-19 | — | — | EP | disclosed |
| US-20140378429-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using Them | RIGEL PHARMACEUTICALS, INC. (US) | 2014-12-25 | — | — | US | disclosed |
| WO-2014057415-A2 | INHIBITORS OF DNA GYRASE FOR THE TREATMENT OF BACTERIAL INFECTIONS | VITAS PHARMA RESEARCH PVT LTD (IN) | 2014-04-17 | — | — | WO | disclosed |
| WO-2013116491-A1 | CARBOXAMIDE, SULFONAMIDE AND AMINE COMPOUNDS AND METHODS FOR USING THEM | RIGEL PHARMACEUTICALS, INC. (US) | 2013-08-08 | — | — | WO | disclosed |
| EP-1194429-B1 | POTASSIUM CHANNEL OPENERS | ABBOTT LAB (US) | 2005-03-30 | — | — | EP | disclosed |
| US-6593335-B1 | Disease than can be ameliorated with a potassium channel opener in a host mammal, comprising administering to the mammal in need thereof a therapeutically effective amount of the compound of claim 1; said disease is epilepsy, Raynaud's | ABBOTT LABORATORIES | 2003-07-15 | — | — | US | disclosed |
| EP-1194429-A1 | POTASSIUM CHANNEL OPENERS | Abbott Laboratories (US) | 2002-04-10 | — | — | EP | disclosed |
| WO-2000078768-A1 | POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2000-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250097-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | CSNK1A1, CSNK1D, CSNK2A1 | TSHR 2934/4885ALDH1A1 2913/4885CYP2A6 1259/4885 |
| US-20150284408-A1 | INHIBITORS OF DNA GYRASE FOR THE TREATMENT OF BACTERIAL INFECTIONS | TOP1, TOP2A, DNASE1 | TSHR 4565/4885ALDH1A1 3693/4885CYP2A6 1317/4885 |
| US-20240300965-A1 | COMPOUNDS | PLAAT2, PLA2G12A, PLA2G1B | TSHR 4736/4885ALDH1A1 2222/4885CYP2A6 2142/4885 |
| US-20220242847-A1 | PYRIDINONE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS AGAINST HIV INFECTED CELLS | PRUNE1, G6PD, ACIN1 | TSHR 4614/4885ALDH1A1 1817/4885CYP2A6 1622/4885 |
| US-11999746-B2 | Compounds | PLAAT2, PLA2G12A, PLA2G1B | TSHR 4736/4885ALDH1A1 2222/4885CYP2A6 2142/4885 |
| US-12258329-B2 | Pyrimidone derivatives as selective cytotoxic agents against HIV infected cells | TYMP, PNP, CD4 | TSHR 4499/4885ALDH1A1 2371/4885CYP2A6 3117/4885 |
| US-20140378429-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using Them | CPT2, SHMT2, CS | TSHR 2596/4885ALDH1A1 397/4885CYP2A6 1104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.